Apr 18 |
Immix Biopharma on Track to Dose NXC-201 Patients in United States
|
Apr 15 |
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
Mar 20 |
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
|
Mar 5 |
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
|
Feb 21 |
Immix Biopharma 12 Month Review Progress Update
|
Feb 8 |
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
|
Feb 7 |
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
|
Feb 6 |
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
|
Feb 5 |
Immix Biopharma looks to raise capital to equity offering
|
Feb 5 |
Immix Biopharma Announces Proposed Public Offering of Common Stock
|